Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis
Arthritis & Rheumatology · 2026-08 · 78 (8) · 1641-1652
DOI: 10.1002/art.70128 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arthritis & Rheumatology, online erschienen am 20.04.2026. Verfasst von Sang T Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Allergy & Immunology, Yale University, New Haven, Connecticut. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Arthritis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Understanding the cellular and molecular mechanisms of T cell activation has enabled the identification of immune checkpoints, such as programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte–associated protein 4 (CTLA‐4), and the development of immune checkpoint inhibitors (ICIs), which have revolutionized cancer therapy. However, ICI cancer treatment is commonly associated with autoimmune side effects, including inflammatory arthritis (IA). ICI‐IA occurs in approximately 6% of ICI‐treated patients and often resembles rheumatoid arthritis phenotypically, although it is generally seronegative. Imaging often demonstrates joint inflammation in patients with ICI‐associated joint pain, even in the absence of joint swelling. The ICI‐IA synovium is characterized by clonal expansion of actively proliferating CD38 hi CD127 ‐ CD8 + T cells and expansion of interleukin‐1β hi macrophages, communicating along CXCL10‐CXCR3 and CCR1‐CCL3/5 axes. Activation of naive CD4 + T cells and impaired Treg cells play a synergistic and amplifying role, especially in the setting of combination ICI (anti–CTLA‐4 plus anti–PD‐1). ICI‐IA has the potential to teach us about mechanisms underlying the biology and evolution of other forms of IA. In this review, we summarize our current understanding of ICI‐IA and propose promising avenues for future research. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Allergy & Immunology, Yale University, New Haven, Connecticut.
- Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, Weill Cornell Medicine, New York, New York.
ORCID-Profile: Anne R Bass
Förderung
- NIAMS NIH HHS
Zitieren
APA
Kim, S. T., & Bass, A. R. (2026). Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis. Arthritis & Rheumatology, 78(8), 1641-1652. https://doi.org/10.1002/art.70128
Vancouver
Kim ST, Bass AR. Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis. Arthritis & Rheumatology. 2026;78(8):1641-1652. doi:10.1002/art.70128
BibTeX
@article{Kim2026,
author = {Kim, Sang T and Bass, Anne R},
title = {Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {8},
pages = {1641--1652},
doi = {10.1002/art.70128}
}
EUVIMED